Navigation Links
Alkaline Phosphatase, shrimp from Roche Applied Science

ProductsAlkaline Phosphatase, shrimp from Roche Applied Science
Company Roche Applied Science
Item Alkaline Phosphatase, shrimp
Price 
Description Request Info
Info Roche Applied ScienceRoche Applied Science
Roche Diagnostics Corporation
P.O. Box 50414
9115 Hague Road
Indianapolis, IN 46250-0414 USA




Call Roche Applied Science to buy products (US and Canada only; other locations use numbers below)
USA Canada 1-866-346-8242
Customer Service: 800-262-1640
Tech Support: 800-262-4911
Fax Number: 800-428-2883
Web Site: http://www.roche-applied-science.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Alkaline Phosphatase Detection Kit from CHEMICON
2. Bovine Phosphatase, Alkaline bovine intestinal mucosa, Unconjugated from Sigma-Aldrich
3. Bovine Phosphatase, Alkaline, Unconjugated from Sigma-Aldrich
4. Shrimp Phosphatase, Alkaline, Unconjugated from Sigma-Aldrich
5. Conjugate Stabilizing Diluent Alkaline Phosphatase from Meridian Life Science, Inc.
6. Calf Alkaline Phosphatase, Calf Intestinal, Unconjugated from Promega
7. Alkaline Phosphatase (E. coli C75) from GE Healthcare, formerly Amersham Biosciences
8. Human Embryonic Stem Cell Marker Antibody Panel. Contains 25 g each of anti-Alkaline Phosphatase, anti-Nanog, anti-Oct-3/4, anti-SSEA-1, and anti-SSEA-4. from R&D Systems
9. Alkaline Phosphatase Stabilizer Solution from BioFX Laboratories, Inc.
10. Sheep Anti-Bovine LACTOPEROXIDASE Polyclonal Antibody, Alkaline Phosphatase Conjugated from AbD Serotec
11. Streptavidin, Alkaline Phosphatase conjugated/tagged from AbD Serotec
Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
CCNI Antibody...
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
3M Imidazole Solution 125 ml...
Biology Products:
(Date:12/19/2014)... --  LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ... bring LaunchKey to market in 2015. LaunchKey ...
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ... technology is accurate, flexible and robust – with the ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... new studies shed light on the complex defense mechanisms ... of which could lead to new, more effective antibiotics ... of antibiotic resistance. The studies, both of which target ... will appear in the February 17 inaugural print issue ...
... San Francisco, is just one of the many American ... trial in India. , The trial is studying ... Under Guidance): a reversible, nonhormonal contraceptive that provides 10 ... procedure. Researchers received approval this week to begin enrolling ...
... at just four months old, babies are able to ... according to brightness, shape, and how close the visual ... very young infants are much more capable of organising ... The study also has implications for understanding certain developmental ...
Cached Biology News:Pair of studies offer new clues to combat antibiotic resistance 2New male contraceptive clears hurdle 2New male contraceptive clears hurdle 3Infants can organise visual information at just four months 2Infants can organise visual information at just four months 3
(Date:12/17/2014)... (PRWEB) December 16, 2014 The ... since 2013, which is why IBISWorld updated its original ... continues to benefit from an intensified focus on environmental ... for new emission standards for power plants and a ... According to IBISWorld Industry Analyst Sarah Kahn, “a range ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
(Date:12/17/2014)... Park, CA (PRWEB) December 17, 2014 ... announces today that it has entered into a ... Midland Company (ADM) to apply DNA2.0’s proprietary protein ... enzyme engineering process. , “We are extremely excited ... ProteinGPS engineering platform. This proprietary bioengineering technology ...
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a primary commercial focus on ... has been granted a Type C meeting with the ... meeting will be held in February 2015.  During this ...
Breaking Biology Technology:Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5